Prognostic Significance of G2/M Arrest Signaling Pathway Proteins in Advanced Non-small Cell Lung Cancer Patients

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Feb 10

PMID 25663895

Citations 6

Authors

Jing Wang

Yuhai Zhang

Shudi Xu

Weijie Li

Zhangqin Chen

Zhe Wang

Xinpeng Han

Yiling Zhao

Shengqing Li

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to retrospectively assess the correlation between the expression levels of proteins involved in G2/M arrest signaling pathways in non-small cell lung cancer (NSCLC) tissue, as determined by immunohistochemical (IHC) methods, and the overall survival of patients with advanced stage NSCLC. IHC analysis of advanced NSCLC specimens was used to determine the expression levels of proteins involved in G2/M arrest signaling pathways, including ataxia telangiectasia mutated (ATM) kinase, ataxia telangiectasia and Rad3-related (ATR) kinase, checkpoint kinase (Chk) 1, Chk2, cell division cycle 25C (Cdc25C), total cyclin-dependent kinase 1 (Cdk1) and active Cdk1 signaling pathways, the latter of which refers to dephospho-Cdk1 (Tyr15) and phospho-Cdk1 (Thr161). Patients were enrolled continuously and followed up for ≥2 years. Univariate analysis demonstrated that the protein expression levels of dephospho-Cdk1 (P=0.015) and phospho-Cdk1 (P=0.012) exhibited prognostic significance, while the expression of the other proteins was not significantly associated with patient survival (ATM, P=0.843; ATR, P=0.245; Chk1, P=0.341; Chk2, P=0.559; Cdc25C, P=0.649; total Cdk1, P=0.093). Furthermore, the patients with tumors exhibiting low expression levels of active Cdk1 survived significantly longer than those with tumors exhibiting high active Cdk1 expression levels (P<0.05). In addition, Cox regression analysis demonstrated that the expression of active Cdk1 [odds ratio (OR), 0.624; 95% confidence ratio (CI), 0.400-0.973; P=0.038] and the pathological tumor-node-metastasis stage (OR, 0.515; 95% CI, 0.297-0.894; P=0.018) were significant independent prognostic factors for NSCLC. Therefore, the results of the present study indicated that active Cdk1 protein is an independent prognostic factor for advanced NSCLC and may validate Cdk1 as a therapeutic target for advanced NSCLC patients.

Citing Articles

CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma.

Stern E, Pines G, Lazar L, Vainer G, Beltran N, Dodi O Biomedicines. 2023; 11(2).

PMID: 36830899 PMC: 9952919. DOI: 10.3390/biomedicines11020362.

Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion.

Lee M, Ham N, Hwang C, Jang J, Lee B, Jeong J Int J Mol Sci. 2022; 23(17).

PMID: 36077072 PMC: 9456023. DOI: 10.3390/ijms23179675.

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology.

Meng Z, Liu X, Wu J, Zhou W, Wang K, Jing Z Evid Based Complement Alternat Med. 2019; 2019:4637839.

PMID: 31275410 PMC: 6558614. DOI: 10.1155/2019/4637839.

Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.

Patel P, Tsiperson V, Gottesman S, Somma J, Blain S Mol Cancer Res. 2018; 16(3):361-377.

PMID: 29330290 PMC: 5835198. DOI: 10.1158/1541-7786.MCR-17-0602.

miR‑342‑5p promotes Zmpste24‑deficient mouse embryonic fibroblasts proliferation by suppressing GAS2.

Zhang C, Liu X, He Q, Zheng H, Xu S, Xiong X Mol Med Rep. 2017; 16(6):8944-8952.

PMID: 28990109 PMC: 5779978. DOI: 10.3892/mmr.2017.7731.

References

Lee K, Min H, Han S, Oh D, Lee S, Kim D . ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2007; 60(3):401-7. DOI: 10.1016/j.lungcan.2007.10.014. View

Koh Y, Jang B, Han S, Kim T, Oh D, Lee S . Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 2010; 5(3):320-5. DOI: 10.1097/JTO.0b013e3181ce684f. View

Xiao D, Zeng Y, Hahm E, Kim Y, Ramalingam S, Singh S . Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells. Environ Mol Mutagen. 2008; 50(3):201-12. PMC: 2656596. DOI: 10.1002/em.20431. View

Buccheri G, Ferrigno D . Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000; 117(5):1247-55. DOI: 10.1378/chest.117.5.1247. View

Fesquet D, Labbe J, Derancourt J, Capony J, Galas S, Girard F . The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 1993; 12(8):3111-21. PMC: 413577. DOI: 10.1002/j.1460-2075.1993.tb05980.x. View

Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S . AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys. 2012; 84(4):e507-14. PMC: 3623267. DOI: 10.1016/j.ijrobp.2012.05.035. View

Abdulkader I, Sanchez L, Cameselle-Teijeiro J, Gude F, Chavez J, Lopez-Lopez R . Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep. 2005; 14(6):1527-31. DOI: 10.3892/or.14.6.1527. View

Smith J, Tho L, Xu N, Gillespie D . The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108:73-112. DOI: 10.1016/B978-0-12-380888-2.00003-0. View

Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A . ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle. 2006; 5(9):994-1000. DOI: 10.4161/cc.5.9.2722. View

10.

Vassilev L, Tovar C, Chen S, Knezevic D, Zhao X, Sun H . Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A. 2006; 103(28):10660-5. PMC: 1502288. DOI: 10.1073/pnas.0600447103. View

11.

Dickhoff C, Hartemink K, van de Ven P, van Reij E, Senan S, Paul M . Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. Lung Cancer. 2014; 85(2):218-23. DOI: 10.1016/j.lungcan.2014.06.005. View

12.

Poon R, Chau M, Yamashita K, Hunter T . The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res. 1997; 57(22):5168-78. View

13.

Travis W, Brambilla E, Riely G . New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013; 31(8):992-1001. DOI: 10.1200/JCO.2012.46.9270. View

14.

Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K . Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem. 2003; 278(17):14806-11. DOI: 10.1074/jbc.M210862200. View

15.

Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H . A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95(8):998-1004. PMC: 2360715. DOI: 10.1038/sj.bjc.6603393. View

16.

Wu W, Fan Y, Kemp B, Walsh G, Mao L . Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998; 58(18):4082-5. View

17.

Choi C, Yang S, Jo H, Song S, Jeon Y, Jang T . Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol. 2012; 23(8):2088-2093. DOI: 10.1093/annonc/mdr606. View

18.

Chow J, Poon R . The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene. 2012; 32(40):4778-88. DOI: 10.1038/onc.2012.504. View

19.

Huang M, Miao Z, Zhu H, Cai Y, Lu W, Ding J . Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther. 2008; 7(6):1440-9. DOI: 10.1158/1535-7163.MCT-07-2116. View

20.

Omolo B, Carson C, Chu H, Zhou Y, Simpson D, Hesse J . A prognostic signature of G(2) checkpoint function in melanoma cell lines. Cell Cycle. 2013; 12(7):1071-82. PMC: 3646863. DOI: 10.4161/cc.24067. View